<DOC>
	<DOCNO>NCT00244816</DOCNO>
	<brief_summary>To evaluate objective response rate duration response weekly Taxoprexin® . To evaluate safety profile weekly Taxoprexin® patient population . To evaluate overall survival patient population . To evaluate time disease progression , time treatment failure patient metastatic choroidal melanoma treat weekly Taxoprexin® Injection .</brief_summary>
	<brief_title>Taxoprexin® Treatment Advanced Eye Melanoma</brief_title>
	<detailed_description>This Phase II open-label study weekly Taxoprexin® Injection patient metastatic choroidal melanoma may previously untreated receive one prior systemic cytotoxic regimen advance disease . Patients may treat previously taxanes . Patients may previously treat immunological agent include IL-2 vaccine . Patients receive Taxoprexin® Injection dose 500mg/m2 intravenously 1-hour infusion weekly first five week six week cycle . Treatment continue progression disease , intolerable toxicity , refusal continue treatment patient Investigator decision .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Patients must histologic cytologic confirmation malignant eye melanoma , document metastatic disease . 2 . Patients must least one unidimensionally measurable lesion . 3 . Patients may previously untreated may receive one prior systemic chemotherapy regimen metastatic disease . Patients may treat previously taxanes . Prior treatment immunotherapy vaccine therapy allow . 4 . At least 6 week ( 42 day ) since prior immunotherapy , cytokine , biologic , vaccine therapy . 5 . At least 4 week ( 28 day ) since prior radiotherapy &gt; 20 % bone marrow prior adjuvant chemotherapy . 6 . Lesions use assess disease status may radiate , must progress radiation therapy . 7 . Patients must ECOG performance status 0 2 . 8 . Patients must least 13 year age . 9 . Patients must adequate liver renal function . 10 . Patients must adequate bone marrow function . 11 . Patients must sign informed consent form indicate aware investigational nature study keep policy institution . 1 . Patients receive prior therapy taxane . 2 . Patients whose site primary melanoma choroid ( eye ) . 3 . Patients past current history neoplasm entry diagnosis , except curatively treat nonmelanoma skin cancer carcinoma situ cervix cancer treat cure diseasefree survival longer 5 year . 4 . Patients symptomatic brain metastasis ( e ) . 5 . Patients pregnant nursing patient practice acceptable method birth control . Patients may breastfeed study . 6 . Patients current active infection require antiinfectious treatment ( e.g. , antibiotic , antiviral , antifungal ) . 7 . Patients current peripheral neuropathy etiology great grade one ( 1 ) . 8 . Patients unstable serious concurrent medical condition exclude . 9 . Patients know hypersensitivity Cremophor . 10 . Patients Gilbert 's Syndrome . 11 . Patients must major surgery within past 14 day . 12 . Patients must receive concurrent chemotherapy , radiotherapy , immunotherapy study . 13 . Known HIV disease infection .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>